The analysis, authored by Camila Strassle and colleagues, arrives at a moment when the longevity field is expanding at a remarkable pace. Startups and established biotechnology firms alike are developing interventions designed to slow or reverse the cellular processes that underlie aging, with the ultimate goals of prolonging life and extending the number of years people remain healthy. Investment has surged, public interest has grown, and the market for products claiming anti-aging benefits has become a multibillion-dollar enterprise. Yet alongside this growth, concerns have mounted that consumers are being sold interventions whose actual clinical value remains unproven.

According to Strassle and her co-authors, the widespread belief that longevity interventions escape regulatory scrutiny is largely mistaken. The researchers argue that products claiming to prevent or reverse aging should follow established FDA approval pathways, the same routes that any other product making comparable claims about human health must navigate. In their view, the regulatory architecture is already in place. What is missing, they contend, is not a legal framework but the willingness of some in the industry to subject their products to the rigorous evidence standards that framework demands.

The Policy Forum makes a pointed argument on this front. Longevity products that claim to prevent or reverse aging, the authors write, should be supported by rigorous evidence of both effectiveness and safety before they reach consumers. The authors put the case bluntly, stating that legitimate industry should welcome such enforcement, and that the public should demand it. This framing reframes the debate: rather than treating regulation as an obstacle to innovation, the authors present it as the very mechanism that would distinguish credible science from unsubstantiated marketing.

If the regulatory pathway is not the real bottleneck, what is? Strassle and colleagues identify a more fundamental obstacle: the sheer difficulty of measuring whether an intervention actually provides meaningful clinical benefits. Aging is not a single disease with a clear endpoint. It is a gradual, multifactorial process, and the outcomes that matter most to patients and consumers, longer life and more years of good health, can take decades to establish. A clinical trial designed to demonstrate that a product extends human lifespan or delays age-related decline would, by its nature, require extraordinarily long follow-up periods, large study populations, and enormous resources.

This measurement problem has deep implications for how the field develops. In the absence of feasible trials measuring hard clinical endpoints such as mortality or disease incidence, many researchers and companies have turned to surrogate markers: epigenetic clocks, telomere length, biomarkers of cellular senescence, and other molecular indicators presumed to reflect biological aging. But the relationship between these biomarkers and actual clinical benefit remains uncertain. A product might shift a molecular clock without adding a single healthy day to a person’s life. Until surrogate endpoints are validated against real-world outcomes, the authors suggest, claims of meaningful benefit rest on shaky ground.

The gray-area perception that has surrounded the industry is not without consequence. When companies believe, or claim to believe, that their products fall outside regulatory jurisdiction, they may market interventions with limited safety testing and no demonstrated efficacy. Consumers, meanwhile, face a marketplace saturated with bold promises and little reliable guidance. The authors’ argument that existing FDA regulations already cover these products carries practical weight: it means that enforcement is possible now, without waiting for new legislation, and that products making disease-related or aging-reversal claims can and should be held to the approval standards that govern drugs and biologics.

The Policy Forum also speaks to a broader tension in biomedical innovation. Regulation is often portrayed as a brake on progress, particularly in fast-moving fields where the pace of discovery outstrips the speed of oversight. Strassle and colleagues invert that narrative. By insisting that longevity products meet established standards of evidence, they argue, regulators would not stifle innovation but channel it, directing investment toward interventions that can genuinely demonstrate benefit and away from products whose claims cannot withstand scrutiny. Innovation through regulation, as the article’s title suggests, is the vision they advance: a longevity industry whose credibility rests on proof rather than promise.

The stakes extend beyond individual consumers to public health at large. If even a fraction of the interventions now under development prove effective at extending healthspan, the implications for aging populations, healthcare systems, and economies would be profound. But realizing that potential depends on the field’s ability to generate trustworthy evidence, and on regulators’ willingness to apply existing authority consistently. The authors’ message to both industry and the public is that the tools for accountability already exist. What remains is for legitimate companies to embrace them, for regulators to enforce them, and for consumers to expect nothing less than rigorous proof before accepting claims that a product can turn back the clock.

As the longevity field matures, the debate over how to evaluate its products is likely to intensify. The Science Policy Forum by Strassle and colleagues offers a clear position in that debate: the question is not whether longevity products can be regulated, but whether the field can measure what truly matters. Until interventions can be shown, through rigorous and patient evidence, to deliver meaningful clinical benefits, the gap between marketing and medicine will remain the industry’s defining challenge.

Subject of Research: Regulatory oversight and clinical evidence standards for human longevity products in the United States

Article Title: Do human longevity products provide meaningful clinical benefits?

Article References: Do human longevity products provide meaningful clinical benefits?. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: longevity, FDA regulation, aging, healthspan, clinical trials, biomarkers, Science Policy Forum, anti-aging products, drug approval, surrogate endpoints, biotechnology, public health

The paper is the product of INPACT!, a network launched in 2023 that brings together more than 120 scientist-innovators from over 20 countries across the European research area, many of them grantees of the European Research Council. The initiative combines the direct experience of researchers who have attempted to commercialise their discoveries with economic analysis of European funding programmes. Among the co-authors are Associate Professor Mehmet Cengiz Onbaşlı of Koç University’s College of Engineering and Professor Erdem Yörük of Koç University’s College of Social Sciences and Humanities, alongside leading researchers from institutions across Europe, including Dario Polli, Professor at Politecnico di Milano, and Amanda Silva Brun, Director of Research at the CNRS, who serve as lead authors.

At the centre of the analysis sits Horizon Europe, the European Union’s flagship research and innovation programme covering the period from 2021 to 2027. The authors argue that although the programme channels enormous resources into excellent science, its funding architecture remains fragmented in ways that penalise researchers attempting to move from laboratory discovery to market application. In particular, they identify an administrative gap between European Research Council Proof of Concept grants, which help researchers explore the practical potential of their fundamental discoveries, and European Innovation Council programmes, which support technology development and business growth. Ideas that successfully navigate one programme can stall at the boundary of the next, losing momentum precisely when commercial promise is greatest.

The Policy Forum’s headline proposal is to bring the ERC Proof of Concept grants under the governance of the European Innovation Council, creating a single, continuous pathway from scientific discovery through technology development to commercialisation. According to the authors, such a restructuring would reduce repeated evaluation cycles, simplify transitions between funding instruments and make support more predictable for both researchers and the investors who back them. Predictability, they contend, is a decisive factor in whether promising ideas attract the sustained capital and institutional patience required to mature into viable ventures.

The urgency of the reform case is underlined by the authors’ observation about where the value of European science is ultimately captured. ERC-funded research, they note, is disproportionately cited in patents filed by United States start-ups rather than European ones, meaning that too much of the latent economic value generated by European public investment is realised elsewhere. Onbaşlı argues that the commercialisation pipeline needed to build many more European unicorns must be paved with complementary incentive mechanisms, so that discoveries made with European funding generate European companies, jobs and societal benefits rather than enriching innovation ecosystems abroad.

Beyond structural reorganisation, the Policy Forum calls for substantially stronger support for early-stage, high-risk innovation. Combined annual funding for the EIC Pathfinder and Transition programmes currently stands at approximately 500 million euros, a figure the authors describe as modest, while their programme-management capacity remains limited compared with advanced research agencies in the United States. The authors recommend reallocating resources towards breakthrough innovation and empowering independent programme managers with greater authority to guide promising projects through their most uncertain phases. This model of empowered programme management, they suggest, draws on the practices of agencies that have demonstrated an ability to nurture transformative technologies by backing exceptional people and ideas over long horizons.

The paper also targets the bureaucratic burden of European funding applications themselves. The authors argue that proposals should be shorter and assessed more directly on the substance of the idea and its potential use, rather than on exhaustive administrative detail that consumes researcher time without improving selection quality. In parallel, they propose that national funding agencies make multi-year commitments to support excellent projects that successfully pass European evaluation but cannot be financed from the available EU budget. This approach would extend the model already established through the Seal of Excellence, a quality label that allows national and regional programmes to co-fund projects judged excellent at European level but left unfunded due to budget constraints.

Yörük frames the underlying problem in stark terms: the challenge is not a lack of excellent science but the weakness of the mechanisms that translate scientific research into economic and societal value. Addressing this, he argues, requires a more continuous pathway from research to proof of concept, entrepreneurship and scale-up, together with academic incentives and institutional structures that support each stage of that journey. The diagnosis shifts responsibility away from individual researchers and towards the systems in which they operate, a framing that has resonated widely among European scientists who have watched colleagues abandon commercialisation efforts or relocate to environments with better innovation support.

Crucially, the authors insist that reforming European funding alone will not be enough. Universities and technology transfer offices must also create conditions in which researchers can pursue innovation without being forced to choose between an academic career and entrepreneurship. The Policy Forum recommends greater recognition of entrepreneurship within academic career structures, improved intellectual-property management, clearer routes to patents, industrial partnerships and spin-offs, and better access to mentoring and entrepreneurial expertise. In many European institutions, entrepreneurial activity remains undervalued in hiring, promotion and tenure decisions, sending a signal that commercial engagement is peripheral to academic life. The authors argue that reversing this signal is essential if Europe is to retain its most commercially minded talent.

Silva Brun emphasises that institutions would benefit from a clearer pathway for translating discoveries into market-ready technologies, with well-defined steps, predictable timelines and streamlined procedures. Making the entire process easier to navigate, she argues, could empower more researchers to transform knowledge into solutions for society, give new momentum to academic careers and enable scientists to play a strategic role in strengthening Europe’s global competitiveness while addressing unmet societal needs. The authors are careful to note that their proposed reforms would not by themselves resolve Europe’s wider constraints in venture capital availability, regulation and business expansion. Nevertheless, they conclude that a more coherent system linking scientific research, technology development and entrepreneurship could help Europe capture far more of the economic and societal value generated by its exceptional research base, turning scientific excellence into a durable engine of European competitiveness. The Policy Forum underwent external peer review and revision before its acceptance and publication in Science on 24 September 2026.

Subject of Research: EU research and innovation policy reform to strengthen the pathway from scientific discovery to commercialisation

Article Title: European researchers set out EU innovation reforms in Science

Article References: European researchers set out EU innovation reforms in Science. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Horizon Europe, European Research Council, European Innovation Council, INPACT!, research commercialisation, science policy, innovation funding, technology transfer, academic entrepreneurship, Proof of Concept grants, Europe competitiveness, Science Policy Forum